Skip to main content

Eli Lilly & Co. (LLY) - Get Eli Lilly and Company Report  posted stronger-than-expected second quarter earnings Tuesday, and boosted its full-year profit forecast, thanks in part to a surge in sales of its key diabetes treatment.

Eli Lilly said earnings for the three months ending in June came in at $1.50 per share, essentially flat to last year but 3 cents ahead of the Street consensus forecast. Group revenues, Eli Lilly said, rpse 1% to $5.637 billion, just shy of analysts' forecast of $5.637 billion, as sales of it Trulicity diabetes treatment rose 32% from last year to top $1 billion.

Looking into 2019, Lilly said its sees full-year earnings in the range of $5.67 to $5.77 per share, but held onto its revenue forecast of $22 to £22.5 billion.

"Lilly's portfolio of newer medicines reached more patients in the second quarter, allowing the company to grow revenue despite headwinds, including the expiration of the U.S. patent for Cialis," said CEO David Ricks. "We are continuing to make significant investments in our business to ensure the success of our recent product launches."

Scroll to Continue

TheStreet Recommends

"At the same time, we are expanding investment in our pipeline in order to develop new medicines that have the potential to more effectively treat patients that have diabetes, cancer, autoimmune disorders and other serious conditions," he added.

Eli Lilly shares were marked 0.03% lower following the earnings release to change hands at $108.89 each, a move that would trim the stock's year-to-date decline to around 5%.